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The potential antimicrobial benefit of high levels of rosmarinic acid (RA) and carvacrol (CA) in oregano (O. onites L.) extract
has been limited until now by poor bioavailability arising from the low aqueous-phase solubility and slow dissolution behaviour
of the lyophilized extract (E). To address this issue, various ratios of phospholipon 90H (P90H) and 1,2-dimyristoyl-sn-glycero-3-
phospho-(1'-rac-glycerol), sodium salt (DMPG)were sonicated, yielding four empty liposomes (L1, L2, L3, and L90). After an initial
selection process, Turkish oregano extract was internalized into the more promising candidates. Each empty liposome, extract-
loaded liposome (LE1, LE2, and LE3), and freeze-dried control (E) was assessed in terms of structure, composition, RA and CA
dissolution profile, storage stability, and, when relevant, zeta potential. Empty liposome L1, which was prepared using P90H and
DMPG in a 1:1 ratio, displayed the most convenient encapsulation traits among the four unloaded types. Loaded liposome LE1,
obtained by combining oregano extract and L1 in a 1:1 ratio, proved superior as a vehicle to deliver RA & CA when compared
against control freeze-dried E and test liposomes LE2 and LE3. Dissolution profiles of the active compounds RA and CA in loaded
liposomes were determined using a semi-automated dissolution tester. The basket method was applied using artificial gastric juice
without pepsin (AGJ, 50rpm, 500mL). The pH value was maintained at 1.5 (37 ± 0.5∘C). Aliquots (5ml) were manually extracted
from parallel dissolution vessels at 1, 3, 5, 7, 10, 15, 20, 25, 30, 45, and 60-minute time points. Dissolution tests, run to completion on
LE1, showed that approximately 99% of loaded CA and 88% of RA had been released. Shorter dissolution times were also noted in
using LE1. In particular, the release profile of CA and RA had levelled off after only 25minutes, respectively, depicting an impressive
3.0–3.3 and 2.3-2.6 rate increase compared to the freeze-dried control extract.The improved dispersibility of RA andCA in the form
of LE1 was supported by particle size and zeta potential measurements of the liposome, yielding 234.3nm and−30.9mV, respectively.
The polydispersity index value was 0.35, indicating a reasonable particle size distribution. To study storage stability, liposomes were
stored (4∘C, 6 months) in amber coloured glass containers (4 oz.). Each container held 30 capsules, which were stored according to
the ICH guidelines prescribed for long-term storage (25∘C± 2∘C; 60%± 5% RH). Triplicate samples were withdrawn after 0, 3, 6, 9,
and 12 months for analysis. Lastly, LE1 displayed good storage stability. The results imply that RA and CA can be conveniently and
routinely delivered via oral and mucosal routes by first internalizing oregano extracts into appropriately engineered liposomes.
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1. Introduction
Recent investigations continue to reveal the merit and benefit
of utilizing natural products in human health issues. Indeed,
the use of plants, parts of plants and isolated phytochemicals
for the prevention, and treatment of various diseases have
been practiced since ancient times. It is estimated that about
25% of the drugs prescribed worldwide ultimately originate
from plants [1].
One natural compound of particular interest is an extract
from oregano (O. onites L.), which contains high amounts
of the antimicrobial compounds rosmarinic acid (RA) and
carvacrol (CA) [2, 3]. Rosmarinic acid is the ester of caffeic
acid and 3,4-dihydroxyphenyl lactic acid [4], while carvacrol
is a monoterpenoid phenol [5]. In addition to antibacterial
and antifungal activity, oregano essential oils also possess
antioxidant, diaphoretic, carminative, antispasmodic, and
analgesic activities [5, 6]. One isolated work has professed
carvacrol as the compound mainly responsible for the bio-
logical activity of oregano [7].
The use of herbal remedies carries along problems,
such as low solubility and hence limited absorption and
bioavailability. Such biologically active compounds are also
prone to in vivo hydrolysis, oxidation, and photolysis, urging
the need for stabilization platforms [8, 9]. Technologies
such as liquid crystal (LC) systems, polymeric and solid
lipid nanoparticles (SLNs), precursors systems for liquid
crystals (PSLCs), liposomes, and microemulsions have been
reported to overcome such limitations [10]. Such drug deliv-
ery platforms improve compatibility, allowing substances
with different physicochemical traits to be used within the
same formulation. Some even make it possible to change the
drug’s apparent traits and hence behaviour in a biological
environment [11].
Among the available breakthrough technologies, lipo-
somes have somehow escaped attention in the deployment of
oregano extracts. Liposomes depict spherical bilayer mem-
branes, which are formed by combining one or more var-
ious amphipathic phospholipids, yielding nanovesicles (i.e.,
nanoliposomes) with an aqueous inner core, a hydrophilic
inner and outer phosphate surface layer, and a hydropho-
bic lipid bilayer [12, 13]. Given these traits, liposomes
can carry hydrophobic drugs, essential oils, herbal com-
plexes, and moisturizers within the bilayer region [14,
15] as well as water-soluble materials within the aque-
ous core. Since the biologically active materials are har-
boured within the liposomal structure, liposome formu-
lations can improve the stability, solubility, and bioavail-
ability of bioactive compounds [16]. For these reasons,
liposomes have been successfully utilized to encapsulate,
deliver, and simultaneously release water-soluble, lipid-
soluble, and amphiphilic materials [10]. Through encapsu-
lation, liposomal carriers have successfully protected thera-
peutic agents from the extreme acidity found at the begin-
ning of the gastrointestinal tract. Like other nanosized
therapeutic agents, liposomal carriers also avoid first-pass
clearance by diversion through the gut-associated lym-
phoid tissue (GALT), thus significantly improving the effi-
ciency of oral drug delivery [17, 18]. As a final noteworthy
point, liposomes are biocompatible and readily biodegrad-
able.
In this study, the extract from Turkish oregano (Orig-
anum onites L.) (hereafter termed oregano) was encapsulated
into liposomes. The objective of this study was to exploit
and optimize the carrier effect of liposomes in order to
impart desirable features to the drug formulation, such as
high encapsulation efficiency, rapid drug release, high release
yields, and improved drug stability. To begin, initial work
focused on preparing and physicochemically characterizing
the optimal liposomal formulation in terms of particle size,
polydispersity, zeta potential, and morphology. Subsequent
work focused on determining the loadings of RA and CA
and their in vitro release kinetics. Finally, liposomes and
freeze-dried extracts were compared to ascertain the merit
of liposomes as carriers for these poorly aqueous-soluble
compounds.
2. Materials and Methods
2.1. Materials. Dried Origanum onites L. herb was obtained
from “I˙nanTarım ECO DAB,” Turkey. Voucher specimens
(No. L270711) are held by the Herbarium of the Department
of Drug Technology and Social Pharmacy, Lithuanian Uni-
versity of Health Sciences. Ethanol (96%) as extraction sol-
vent was purchased from Vilniaus degtine˙ (Vilnius, Lithua-
nia). Phospholipon 90H (PL 90H) and 1,2-dimyristoyl-sn-
glycero-3-phosphorylglycerol sodium salt (DMPG-Na) were
graciously provided by LipoidAG (Ludwigshafen, Germany).
Purified water used for sample preparation and HPLC runs
was produced using a Super Purity Water System (Millipore,
USA).HPLC eluents:methanol (99.95%)was purchased from
Carl Roth GmbH (Karlsruhe, Germany) and acetic acid
(99.8%) from Sigma-Aldrich (St. Louis,MO,USA). Standards
for HPLC analysis: carvacrol (>98%) was purchased from
Sigma-Aldrich (St. Louis, MO, USA) and rosmarinic acid
(>98%) from ChromaDex (Santa Ana, TX, USA).
2.2. Methods
2.2.1. Preparation of Oregano Ethanol Extract. Oregano herb
was ground in a IKA Works brand A11 model cross beater
mill-type basic grinder (Guanghou,China) and sieved using a
Retsch brandAS 200model basic vibratory sieve shaker (UK)
equippedwith a sieve (125𝜇m). Powderedmaterial (100g) was
extracted with 90% (v/v) ethanol (1L) in a round bottom flask
via the technique of heat-reflux extraction (95∘C, 4h). The
heat source was a Memmert brand WNB7 model water bath
(Memmert GmbH & Co. KG, Schwabach, Germany). The
recovered extract was filtered via vacuum. These conditions
were previously deemed most convenient for extracting RA
and CA from Turkish oregano [19].
2.2.2. Preparation of Empty Liposome (L). The liposome was
prepared using a film technique as per the original method
of Bangham [20]. Each phospholipid was dissolved using
2:1 (v/v) chloroform/methanol (30mL) in separate round-
bottomed flasks. Phospholipid from these stocks was com-
bined in various ratios (300mg phospholipid in total; see
Table 1 for weight ratios).The solvents were removed (15 min,
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Table 1: Empty liposome (L), Oregano extract (E), and loaded liposome data: composition, weight ratio, mass and volume information, and
formulation codes.
Formulation Composition Ratioa Weight (mg, ml) Code
Liposome P 90H∗ - 300mg L90
Liposome P 90H:DMPG∗∗ 1:1 L1
Liposome P 90H:DMPG 1:2 L2
Liposome P 90H:DMPG 1:3 L3
Ethanolic Oregano herb extract E 200ml E
Liposome formulation L90:E 1:1 LE90
Liposome formulation L1:E 1:1 LE1
Liposome formulation L1:E 1:2 LE2
Liposome formulation L1:E 1:3 LE3
aPhospholipid ratio for L series, liposome/extract ratio for LE series.
∗P90H (Phosphatidylcholine).
∗∗ DMPG (Na DMPG; dimyristoyl phosphatidylglycerol, sodium salt).
25∘C) using a Heidolph brand rotary evaporator (Schwabach,
Germany). The thin film, which had formed along the
inner wall of the flask, was dispersed in purified water with
some shaking. The suspension was frozen and freeze-dried
overnight (-80∘C) using a Martin Christ brand Alpha 2-4
LD Plusmodel (Germany) lyophilizer.The procedure yielded
empty liposomes L1, L2, L3, and L90.
Chloroform and methanol were used in the above pro-
cedure as opposed to nontoxic solvents and water for the
simple reason that prior experience had routinely revealed
best results when manipulating phospholipids. Rotary evap-
oration and lyophilisation served to rid the empty liposomes
of virtually all of the undesirable solvent prior to engaging
subsequent steps.
2.2.3. Preparation of Extract-Loaded Liposome Formulations
(LE). Topromote uniformparticles andminimize clustering,
empty liposomeswere loadedwith ethanolicOriganum onites
L. extracts according to the thin film hydration method
[21]. Variables included the phospholipid composition, the
liposome-to-extract ratio, and the time and shear rate of
the homogenization process. To prepare loaded liposomes
LE90, LE2, LE1, and LE3, freeze-dried empty liposome L90
or L1 was dispersed into the ethanolic oregano extract at
prescribed weight ratios (Table 1). The resultant mixture was
homogenized (10k rpm, 5 min) using a Wise Tis HG-15D
model homogenizer. Ethanol was removed under reduced
pressure (15 min, 25∘C) using a rotary evaporator (Heidolph,
Schwabach, Germany) to form a thin film on the inner walls
of the flask. The thin film was dispersed into purified water
and freeze-dried overnight (-80∘C) using a Martin Christ
brand Alpha 2-4 LD Plus model freeze-dryer (Germany). L2
and L3were not pursued in this study to encapsulate the drug,
as L1 and L90 proved more convenient.
2.2.4. Characterization of Liposome Formulations. Physical
size traits of the liposome dispersions were assessed using
a Malvern brand ZS 501 model Particle Sizer dynamic
light scattering (DLS) instrument (Malvern, Worcestershire,
UK); liposome dispersion (0.1mL) was diluted in purified
water (1mL). The mean particle size, size distribution, and
polydispersity index were expressed as an average of six trials.
Zeta potential was also measured (25∘C, 90∘ angle) using a
Malvern brand ZS 501 model Zeta-sizer instrument (DLS).
The results of the analysis were expressed as a mean value of
10 measurements.
2.2.5. Scanning Electron Microscopy (SEM) of Liposome
Dispersions. Scanning electron microscopy (SEM) (LEO
SUPRA 35 VP) images of liposomes were acquired at two
magnifications (3.5 & 10 kx) using a Zeiss brand electron gun
(working distance 12.1mm and 8 mm; SE2 detection mode;
beam voltage 10kV). To prepare samples for imaging, dry
liposome dispersions were sputter coated using carbon.
2.3. Quantitative Analyses
2.3.1. Powder Preparation for HPLC Analysis. To quantify
RA and CA loadings, liposomes were accurately weighed
(100mg) and dispersed in methanol (10mL). The contents
were extracted (10 min) using an ultrasound bath (Memmert
WNB7 water bath, Memmert GmbH & Co. KG, Schwabach,
Germany). The extract was passed through a nitrocellulose
filter (0.45𝜇m) and submitted to HPLC analysis.
HPLC analysis was carried out using aWaters brand 2695
model chromatography system (Milford, USA) equipped
with a Waters brand 996 model PDA detector. Data were
collected and analyzed using Empower 2 Chromatographic
Manager System software (Waters Corporation, Milford,
USA). Sampleswere chromatographed along aACE 5C18 250× 4.6mmcolumn (AdvancedChromatographyTechnologies,
Aberdeen, Scotland).
2.3.2. HPLC Conditions to Determine RA. The dual solvent
mobile phase was composed of solvent A (methanol) and
solvent B (0.5 % (v/v) acetic acid in water). The following
linear gradient elution profilewas used: 95%A/5%B–0min,
40 % A/60 % B – 40min, 10 % A/90 % B – 41 - 55 min, and 95
%A/5%B – 56min.The flow rate was 1mL/min and injection
volume was 10 𝜇L. RA in the effluent was determined at a
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wavelength of 329nm. Quantification was carried out using
the external standard method. A linear calibration curve
was prepared (R2=0.999918), and the underlying peak areas
permitted quantification [19].
2.3.3. HPLC Conditions to Determine CA. A single mobile
phase was composed of methanol and water (60/40, v/v).The
flow rate was 0.6 mL/min and injection volume was 10 𝜇L.
CA absorption was measured at 275 nm. The quantification
was again carried out using the external standardmethod and
associated calibration curve (R2=0.999) [19].
2.3.4. Product Yield (%w/w) and Encapsulation Efficiency
(%w/w). Product yield was defined as the weight of lipo-
somes after the process of internalization divided by the
weight of liposome, which in theory should have been
measured had encapsulation been%100 effective andmaterial
losses zero. Yields were calculated as
Yield (%) = Dry weight of extract loaded liposomal nanoparticles formed after encapsulation
Summed dry weight of empty liposome and extract added prior to encapsulation
× 100 (1)
where the dry weight of empty liposome refers to the
lyophilized 1:1 PL 90H/DMPG system, the dry weight of the
loaded liposome refers to lyophilized extract-encapsulated
liposome, and the dryweight of extract refers to residue in the
ethanolic oregano extract following removal of solvent. The
yield of freeze-dried extract E was defined differently in view
of the absence of any liposomes. Here, the yield was simply
the ratio of the dry weight of dispersed E divided by the total
dry weight initially added to the dispersion medium.
Encapsulation efficiency (%) was defined differently so as
to emphasize the bioactive material as opposed to the entire
liposome [22]:
%EE
= [(weight of bioactive compound added to load the liposomes – weight of unincorporated bioactive compound)(weight of bioactive compound added to load the liposomes) ]
× 100%
(2)
where the bioactive compound is RA, CA, or both extract
materials depending on how the quantification is defined and
carried out.
Quantitative estimation of RA and CA in loaded lipo-
somes was carried out using HPLC. Liposomal formulation
(100mg) was suspended in a 1:1 (v/v) 96% ethanol / methanol
cosolvent (10ml). The suspension was sonicated (10 min),
filtered through a nitrocellulose membrane (0.22𝜇m), and
analysed as described below.
2.3.5. Preparation of Capsules Fillings. The composition of
capsules is shown in Table 1. Capsules were filled using a
Capsuline brand manual capsule filling machine (USA).
2.3.6. Determination of Dissolution Profiles and Their Vari-
ability. Dissolution profiles of the active compounds RA and
CA in loaded liposomes were determined using a SOTAX
brand AT 7 smart model semiautomated dissolution tester
(Switzerland).The basket method was applied using artificial
gastric juice without pepsin (AGJ, 50rpm, 500mL). The pH
value was maintained at 1.5 (37 ± 0.5∘C). Aliquots (5ml)
were manually extracted from parallel dissolution vessels at
1, 3, 5, 7, 10, 15, 20, 25, 30, 45, and 60 minute time points,
filtered through a nitrocellulose membrane (0.45𝜇m), and
quantified via HPLC. The dissolution media in each vessel
was topped off with fresh dissolution fluid (5mL) to restore
the original volume. The mean value of six trial runs and
a standard deviation for each type of nanoparticle were
calculated. The evaluation of dissolution profiles was carried
out in triplicate.
2.3.7. Evaluation of Stability. To study storage stability, lipo-
somes were stored (4∘C, 6 months) in amber coloured glass
containers (4 oz.). Each container held 30 capsules, which
were stored according to the ICH guidelines prescribed for
long-term storage (25∘C ± 2∘C; 60% ± 5% RH). Triplicate
samples were withdrawn after 0, 3, 6, 9, and 12 months for
analysis. Parameters were assessed such as particle size, zeta
potential, PDI, %EE of CA & RA, organoleptic state, average
weight, and drug content.
2.4. Statistical Analysis. Rawdatawas assessed usingANOVA
statistical testing (specifically one-way analysis of variance)
and Tukey’s multiple comparison test. For this purpose,
a software package was utilized (Prism v. 5.04, GraphPad
Software Inc., La Jolla, CA, USA) with statistical significance
being defined as p < 0.05.
3. Results and Discussion
3.1. Preparation and Characterization of Liposome. In com-
mencing this work, initial emphasis had been placed on
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Table 2: Characteristics of various empty and Oregano extract-loaded liposomes.
Formulation Mean Size (nm) Zeta potential (mV) PDI (polydispersity index)
L90 1176±148.6++ 1.53± 0.14++ 0.23±0.02⧫
L1 107.4±0.45 -35.7± 1.08 0.25±0.04 ⧫
L2 97.48±0.23 -40.5± 2.08 0.34±0.02⧫
L3 43.9±0.45 -49.5±4.08 0.54±0.02⧫
E 103.7±23.02 -23.7±7.47 0.65±0.03
LE90 2660±17.02 12.45±7.47 ++ 0.33±0.06 ⧫
LE1 234.3±35.56 + -30.9±9.12 0.35±0.02 ⧫
LE2 266.1±17.02 + -28.5±0.47 + 0.47±0.06
LE3 634.3±35.56 + -25.9±2.12 + 0.57±0.02 ⧫
∗RA: rosmarinic acid.
∗∗CA: carvacrol.
+ p ≤ 0.05 vs L2, L1, and L3.
++ p ≤ 0.05 vs L1, L3, L2, E, LE1, LE2, and LE3.
⧫ p ≤ 0.05 vs E.
preferentially preparing zwitterionic liposomes comprised of
P90H, the reason being that biological surfactants can be
arranged in decreasing order of toxicity according to the com-
monly observed trend for oral and parenteral applications:
cationic > anionic > amphoteric ≥ nonionic [23–27]. When
initial testing revealed inconveniences in using only P90H,
a combination of P90H and anionic DMPG was introduced,
with emphasis being placed on using the minimal amount
of DMPG needed to resolve the inconvenience. Following
more iteration, a 1:1 P90H/DMPG ratio (L1) proved itself
to be the liposome of choice for conducting subsequent
extract-encapsulation studies, as this liposome displayed
favorable mean particle size, zeta potential, and PDI traits.
Table 1 is a formulation summary of some of the finalized
liposome-based candidates used in this study.The subsequent
internalization ofOriganum onites L. was successfully carried
out via the method of Fricker et al. using empty liposomes
L90 and L1 to yield extract-loaded liposomes LE90, LE1,
LE2, and LE3. Several iterations were necessary and minor
protocol variations were implemented to arrive at cluster-
free, reasonably uniform particles and a good level of extract
internalization [21].
Summarized by Table 2, standard methods were used
in this study to ascertain the particle size, polydispersity
index (PDI), and zeta potential of (i) empty (L90) and
extract-loaded (LE90) liposomes prepared from P90H, and
(ii) empty (L1) and extract-loaded (LE1, LE2, LE3) liposomes
prepared from 1:1 (wt/wt) P90H/DMPG (videTable 1 formore
information regarding composition).
The mean particle size displayed considerable variation
in response to the liposome composition and extract loading.
Among the empty liposomes, L90, which comprised P90H,
had the largest particles.The particle size of empty liposomes
was much smaller for P90H/DMPG combinations and the
average diameter varied with the phospholipid ratio. The
highestmean particle size for empty P90H/DMPG composite
liposomes was L1. L1 was in fact two times larger on average
than L3 (Table 2).The largest mean particle size (2660 ± 17.02
nm) was obtained in the case of LE90, whereas the smallest
mean particle size corresponded to LE1 (234.3 ± 35.56 nm).
The polydispersity index (PDI) value is important in that
it shows the size distribution of the liposomes, which can
correlate to stability. A PDI value of 1.0 indicates a very broad
size distribution or presence of large particles or aggregates,
which could sediment. An optimum PDI value is 0.30 or less,
signifying that 66.7% of all nanovesicles are the same size
[28].The PDI values obtained in this work ranged from 0.2 to
0.65 (Table 2), showing high-to-medium homogeneity of the
liposome particle sizes. The highest PDI value was observed
over the course of dispersing the freeze-dried extract. PDI
values for LE90 and LE1 were 0.33±0.06 and 0.35±0.02,
respectively. The PDI values of LE1 and LE90 were more
or less the same. The PDI generally revealed a respectable
but occasionally overly excessive size distribution in selected
empty liposomes. The value ranged from 0.23±0.02 for L90
to 0.54±0.02 for L3. The highest PDI value was observed in
the freeze-dried extract, indicating a heterogeneous system.
Such a finding was not surprising, as the bulk process
of freeze-drying would be anticipated to seed substantial
particle size heterogenity compared to nanoparticle systems
such as liposomes. The approximate PDI values for LE90
(0.33) and LE1 (0.35) indicated a relatively homogeneous size
distribution.The differing phospholipid compositions in L90
and L1 did not affect the size distribution value to a significant
degree, which is in agreement with other studies [29].
The zeta potential is an important parameter used to
evaluate the dispersional stability of liposomal formulations.
It characterizes the particles surface charge and gives an
indication about repulsive forces between particles, thus
allowing one to predict the stability of dispersions [29]. As
a general rule of thumb, zeta potential values of < -30mV
and > 30mV create stable systems because the high surface
charges induces repulsion, thereby preventing aggregation
[16]. Smaller absolute zeta values may also suffice if the
electrical double layer thickness is comparable to or greater
than the particle size. In this work, the zeta potential varied
between -49.5±2.12mV for LE3 and 12.45±7.47mV for LE90
(Table 2). These variations corresponded to differences in
lipid ratio of the various liposome formulations. Potentials
ranged from -40.5±2.08mV for L2 to +1.53±0.14mV for L90.
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(a) (b) (c)
Figure 1: SEM micrographs of freeze-dried Oregano extract E (a) liposome vehicles L1, (b) liposome LE1, and (c) formulations.
(a) (b) (c)
Figure 2: Product yield and encapsulation efficiency of various liposome formulations.
The relatively positive zeta potential of LE90 was not surpris-
ing in that the liposome was deficient in anionic surfactant. It
also followed to reason that the small absolute zeta potential
of LE90 had prompted coalescence and large average particle
sizes (just as in the case of LE2). Given that the composite
phospholipid liposomes (empty and loaded) had negative
surface charges, the difference could be attributed to the
presence of anionic DMPG. It is unclear as to what extent
the carboxylic acid of RA contributes to the zeta potential;
however, given that the zeta potential in transcending from
L90 to LE90 was still positive, it can be assumed that RA’s
contribution is minor compared to DMPG. This assessment
potentially conflicts with previous work in which the oregano
herb is professed to be a major contributor of the overall
zeta potential [30]. Subtle trait differences between themodel
systems of the current work and cited work could likely
explain the conflicting observation. All in all, L1, L2, LE1, and
LE3 all yielded substantially negative zeta potentials and small
particle sizes, indicative of good stability against aggregation.
Such results are consistent with another group [31].
SEM is the most convenient visual technique to probe
the mean size and the surface morphology of particles
[24]. The morphology of oregano extract-loaded LE1, freeze-
dried E, and empty liposome L1 are shown in Figure 1.
SEM imagery showed that most particles in LE1 were near-
spherical and uniform in size with smooth surfaces. In cases
of agglomeration, the agglomerate sizes ranged up to 1 𝜇m.
In the case of LE1, agglomerates were still composed of
small particles in the nanometer range. The arrangement of
the nanoparticles formed an apparent porous network. L1
particles were spherical and uniform in shape and somewhat
smaller than LE1. SEM also confirmed that the anionic
lipid contribution in L1 appeared to yield better shaped
particles with less interparticle interactions; such an observa-
tion would support the mean particle size differences noted
between L90 and L1. Incorporation of oregano extract into
L1 did not appear to have caused any morphological changes
or crystal formation. Morphological analysis of the freeze-
dried extract powder revealed the absence of small spherical
granules, which implied poor dispersibility and hence low
bioavailability.
3.2. Product Yield and Encapsulation Efficiency Determina-
tion. As shown in Figure 2, the best yield corresponded
to LE1, which was approximately 1.2 times greater than
E, LE90, LE2, and LE3 (given p<0.05). In terms of yield,
there was no significant difference between LE90 and LE3
(p<0.05). Interestingly, higher extract to liposome ratios
(LE2, LE3) prompted lower yields. The lowest product yield
corresponded to freeze-dried E (vide method section for
further discussion).
The encapsulation efficiency of RA and CA was deter-
mined independently of each other (vide methods section).
As illustrated in Figure 2, efficiencies varied between 65 ±
0.78 % and 90 ± 1.2 % in the case of RA. The highest EE
for RA appeared to correspond to LE1, however, there was
no statistically significant difference in EE between LE1 and
LE2 (given p<0.05). The lowest EE clearly corresponded to
LE90. In the case of CA, EE’s varied between 40.23±0.35%
and 67.4±0.56%. The highest EE for CA again corresponded
to LE1 (p<0.05) and this time encapsulation was clearly less
efficient in the case of LE2. The same trend was noted for CA
in the sense that LE90 fared poorest. As a general observation,
the encapsulation efficiency varied according to the liposome
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(a) (b)
Figure 3: (a) In vitro release of CA from LE1 and E. (b) In vitro release of RA from LE 2 and E.
type and size. It is generally accepted that the encapsulation
efficiency of the active substances within liposomal structure
can be affected by the size and/or specific surface area of
liposome [32–35].
The highest encapsulation efficiency of RA & CA was
observed in LE1, a 1:1 mixture of zwitterionic and anionic
surfactant. It is unclear why better encapsulation of the
carboxylic acid-bearing RA was not noted in LE90, given the
lack of any anionic surfactant in the L90 liposomal structure.
Still, RA does feature unusual behaviour, which might serve
as a clue. In particular, other studies conducted onRA showed
that RA could collapse the fluid space of bilayers through
formation of interlayer bridges [16, 36]. Similar results were
reported in the case of pistachio green hull ethanolic extract-
loaded liposomes [16] and other similarities were cited in
previous studies, which reported the high encapsulation
efficiency of liposomes [29, 37, 38].The lower EE forCA could
be rationalized on the basis of its greater hydrophobicity
compared to RA. It is conceivable that CA loads only in the
lipid bilayer, which depicts a smaller volume space compared
to the aqueous core of the liposome.
3.3. In Vitro Drug Release. Figures 3(a) and 3(b) illustrate the
in vitro dissolution profiles of LE1 and freeze-dried extract
E. CA in LE1 dispersed into the solvent 3.0–3.3 fold more
compared to E (Figure 3(a)). The data showed that LE1
had released 75% of its CA after only 5 minutes. Similar
results were obtained previously [33, 39].The same trend was
observed with RA in the sense that LE1 prompted a 2.3–2.6
fold greater solution-phase concentration of dispersed RA
compared to the control sample E (Figure 3(b)). Again, LE1
had released 80% of its RA content after only 5 minutes.
In summary, LE1 displayed a significantly better in vitro
dissolution profile and dissolution rate compared to the
freeze-dried control sample E. Also noteworthy is that the
release of CA from LE1 had approached 100% after 25
minutes. The improved release traits appeared to have rested
on the liposome’s ability to enhance the solubility or at
least the dispersibility of hydrophobic and hydrophilic active
compounds [29]. Such a claim is not without precedent; it has
already been noted that the higher apparent dissolution and
rate of dissolution of drugs in liposome formulations show
Table 3
(a) Kinetic analysis of RA release profiles of LE1 and E
Kinetic Model LE1 E
Zero-order
R 0.8918 0.6909
R2 0.8086 0.6033
First-order
R 0.9993 0.8609
R2 0.9987 0.8033
(b) Kinetic analysis of CA release profiles of LE1 and E
Kinetic Model LE1 E
Zero-order
R 0.9018 0.6709
R2 0.8186 0.6233
First-order
R 0.9903 0.7609
R2 0.9907 0.7033
promise as phospholipid carriers for enhancing the in vivo
availability of active compounds [38, 40].
3.4. Release Kinetics. To better elucidate the release kinetics
of CA & RA, the drug release versus time profiles of LE1 and
E were shape-fitted against zero-order and first-order kinetic
models (Tables 3(a) and 3(b)). The best correlation corre-
sponded to the first-ordermodel, implying the dependence of
rate versus the concentrations of CA&RA. Such findingsmay
also have reflected a pseudo first-order model, which escaped
detection by typical kinetic analysis. Irrespective of whether
or not the kinetics herein are first-order or pseudo first-order,
the end result implies that the drug release rate will slow in
time as the concentration of CA & RA diminishes.
Had zero-order kinetics been noted, certain benefits
could have been claimed for this liposome-based technol-
ogy. For instance, constant time-release kinetics could have
imparted an additional element of convenience to drug
delivery inmedicine and agriculture. As it stands, the findings
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Table 4: LE1 storage stability data under different conditions (4∘C and 25∘C).
Conditions Time (Mon) Mean Size (nm) Zeta potential (mV) PDI EE RA EE CA
4∘C±0.5∘C/60% ± 5% RH1 Initial 234.3±35.56 -30.9 ± 9.12 0.35±0.02 90.12±0.13 65.5±1.2
1 236.9±12.5 -31.0±1.2 0.34±0.03 90±1.2 65.5±3.4
3 234.1±23.12 -33.8±4.6 0.33±0.02 89.9±2.3 65.4±1.4
6 240.1± 23.5 -32.78±3.9 0.33±0.01 89.9±1.3 65.3±0.3
25∘C±2∘C/60% ± 5% RH1 Initial 234.56±12.5 -32.6 ± 9.12 0.32±0.01 90.15±0.45 66.2±1.6
1 235.01±16.7 -33.8±7.45 0.31±0.01 90.1±0.34 66±1.9
3 236.7±12.6 -32.0±2.4 0.3±0.02 89.1±1.2 65.9±2.4
6 239.98±9.4 -33.9±2.3 0.32±0.01 89.9±1.2 65.8±3.5
9 239.99±8.2 -33.1±4.7 0.31±0.02 87.7±3.4 64.9±2.4
12 240.0±2.4 -33.0±5.6 0.33±0.01 87.9±5.6 64.7±5.6
All values are mean values of triplicate samples of each time point.
1RH: relative humidity.
in Tables 3(a) and 3(b) imply that LE1 could serve as reservoir
system for the continuous delivery of encapsulated CA and
RA. However, the release kinetics will not be constant over
time and must be monitored.
3.5. Storage Stability. Freeze-dried control extract sample
E proved relatively hygroscopic in view that its moisture
content had increased 1.4-fold (p<0.05) during the 28 days
of stability testing in comparison to freshly prepared samples
of E. Testing of E was terminated at this point because of the
high moisture content.
Compared to control sample E, liposome LE1 was not
hygroscopic. Hence, the stability of LE1 could be tested over
a much longer storage period of 12 months at two different
temperatures (4∘C & 25∘C ± 2∘C; 60% ± 5% RH) (Table 4).
In all aspects of testing, LE1 appeared physically, chemically,
mechanically, and organoleptically stable.Themean size, zeta
potential, PDI and EE of RA & CAwere all comparable at the
various time points. The disintegration times of the capsules
were also independent of the storage period. With respect to
mean particle size, only a 2.38% size increase (i.e., final size
240.3 ± 30.56 nm) was noted over the 12-month incubation
period at 25∘C ± 2∘C and 60% ± 5% RH. In fact, particle
size showed no statistically significant difference during the
first 4 months. The same trend was noted at 4∘C. PDI
values also varied little during incubation at both temperature
conditions, implying good stability. Indeed, no statistically
significant difference was observed after the first month of
storage (p >0.05). Paralleling the above was also the EE of RA
& CA. The EEs were rock stable during the first 6 months of
storage under both storage conditions. After 9 months, the
EE of RA had diminished by only 3% compared to the zero
time point. The EE of CA had diminished to a lesser degree
than RA, implying near-perfect stability. Previous work has
shown that stability can be challenged by long-termoxidation
[11] so it appears that the liposomes of the current work are
resistant to some extent. The slightly higher loss in EE of
RA compared to CA could be related to RA’s higher water-
solubility; constant partitioning of RA into the aqueous core
could conceivably have led to hydrolytic degradation. The
same tendency has been reported for allicin encapsulated in
liposomes; EE’s had diminished over the course of 50 days of
storage at 4∘C [35].
4. Conclusions
In this study, various liposomal formulations were pre-
pared with and without oregano extract. On the basis of
physicochemical, morphological, and stability analyses, LE1
represented the best candidate for implementation as a ther-
apeutic delivery agent. In terms ofmean particle size, LE1 was
appropriately sized to showgoodbiological efficacy and about
4-6 times smaller than the other formulations. Moreover,
the PDI value of LE1 indicated a sufficiently homogeneously
disperse collection of particles. LE1 was a stable system, with
a zeta potential at a sufficiently negative value. SEM imagery
of LE1 visually supported the above claims in that it showed
relatively homogeneously-sized nanospheres. In terms of the
in vitro release profile, RA and CA incorporation into L1
liposomes dramatically improved the dispersion/dissolution
traits of RA and CA compared to the freeze-dried control
extract E. Without question, correlation studies indicated
that the release kinetics of RA and CA proceeded via an
apparent first-order model. Lastly, LE1 was remarkably stable
over a 12-month storage period even under conditions of
substantial humidity.These findings indicate that a liposomal
oregano extract approach can improve the dispersibility and
dissolution rate of RA and CA, thus implying a potentially
promising alternative technology for the oral and mucosal
application of such therapeutics.
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